Modest meeting sees only two drugs recommended by CHMP

The drug was third to market in the class, coming behind first place winner Aimovig (erenumab) from Amgen and second entrant Ajovy (fremanezumab) from Teva.

Biohaven gets FDA approval for migraine drug Nurtec ODT

A successful outcome in those studies would make the drug a potential competitor to three CGRP inhibitors given by subcutaneous injection – Amgen/Novartis’ Aimovig (erenumab), Teva’s Ajovy (fremanezumab) and

Lundbeck gets US approval for migraine drug at heart of Alder takeover

Teva has however claimed an FDA approval for a three-month regimen for Ajovy. ... Teva meanwhile said Ajovy made $96m last year, while Lilly reported Emgality sales of $163m.

Teva’s weak pipeline hit by Tourette’s drug trial failure

Drug wasn't able to improve on placebo. Teva’s effort to reinvigorate its business with new product launches has suffered a setback after a drug for Tourette’s syndrome failed ... Deutetrabenazine was acquired by Teva when it bought  Auspex Pharma

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]